These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 22184381)

  • 1. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.
    Choueiri TK; Ross RW; Jacobus S; Vaishampayan U; Yu EY; Quinn DI; Hahn NM; Hutson TE; Sonpavde G; Morrissey SC; Buckle GC; Kim WY; Petrylak DP; Ryan CW; Eisenberger MA; Mortazavi A; Bubley GJ; Taplin ME; Rosenberg JE; Kantoff PW
    J Clin Oncol; 2012 Feb; 30(5):507-12. PubMed ID: 22184381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
    Herbst RS; Sun Y; Eberhardt WE; Germonpré P; Saijo N; Zhou C; Wang J; Li L; Kabbinavar F; Ichinose Y; Qin S; Zhang L; Biesma B; Heymach JV; Langmuir P; Kennedy SJ; Tada H; Johnson BE
    Lancet Oncol; 2010 Jul; 11(7):619-26. PubMed ID: 20570559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.
    Heymach JV; Johnson BE; Prager D; Csada E; Roubec J; Pesek M; Spásová I; Belani CP; Bodrogi I; Gadgeel S; Kennedy SJ; Hou J; Herbst RS
    J Clin Oncol; 2007 Sep; 25(27):4270-7. PubMed ID: 17878479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.
    Coleman RL; Moon J; Sood AK; Hu W; Delmore JE; Bonebrake AJ; Anderson GL; Chambers SK; Markman M
    Eur J Cancer; 2014 Jun; 50(9):1638-48. PubMed ID: 24709487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.
    de Boer RH; Arrieta Ó; Yang CH; Gottfried M; Chan V; Raats J; de Marinis F; Abratt RP; Wolf J; Blackhall FH; Langmuir P; Milenkova T; Read J; Vansteenkiste JF
    J Clin Oncol; 2011 Mar; 29(8):1067-74. PubMed ID: 21282537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer.
    Horti J; Widmark A; Stenzl A; Federico MH; Abratt RP; Sanders N; Pover GM; Bodrogi I
    Cancer Biother Radiopharm; 2009 Apr; 24(2):175-80. PubMed ID: 19409038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study.
    Boér K; Láng I; Llombart-Cussac A; Andreasson I; Vivanco GL; Sanders N; Pover GM; Murray E
    Invest New Drugs; 2012 Apr; 30(2):681-7. PubMed ID: 20830502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy.
    Ahn JS; Lee KH; Sun JM; Park K; Kang ES; Cho EK; Lee DH; Kim SW; Lee GW; Kang JH; Lee JS; Lee JW; Ahn MJ
    Lung Cancer; 2013 Dec; 82(3):455-60. PubMed ID: 24075125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.
    Sonpavde G; Pond GR; Choueiri TK; Mullane S; Niegisch G; Albers P; Necchi A; Di Lorenzo G; Buonerba C; Rozzi A; Matsumoto K; Lee JL; Kitamura H; Kume H; Bellmunt J
    Eur Urol; 2016 Apr; 69(4):634-641. PubMed ID: 26264159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.
    Petrylak DP; de Wit R; Chi KN; Drakaki A; Sternberg CN; Nishiyama H; Castellano D; Hussain S; Fléchon A; Bamias A; Yu EY; van der Heijden MS; Matsubara N; Alekseev B; Necchi A; Géczi L; Ou YC; Coskun HS; Su WP; Hegemann M; Percent IJ; Lee JL; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Del Muro XG; Rodriguez-Vida A; Cicin I; Harputluoglu H; Widau RC; Liepa AM; Walgren RA; Hamid O; Zimmermann AH; Bell-McGuinn KM; Powles T;
    Lancet; 2017 Nov; 390(10109):2266-2277. PubMed ID: 28916371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).
    Lee JS; Hirsh V; Park K; Qin S; Blajman CR; Perng RP; Chen YM; Emerson L; Langmuir P; Manegold C
    J Clin Oncol; 2012 Apr; 30(10):1114-21. PubMed ID: 22370318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.
    Petrylak DP; de Wit R; Chi KN; Drakaki A; Sternberg CN; Nishiyama H; Castellano D; Hussain SA; Fléchon A; Bamias A; Yu EY; van der Heijden MS; Matsubara N; Alekseev B; Necchi A; Géczi L; Ou YC; Coskun HS; Su WP; Bedke J; Gakis G; Percent IJ; Lee JL; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Garcia Del Muro X; Rodriguez-Vida A; Cicin I; Harputluoglu H; Tagawa ST; Vaishampayan U; Aragon-Ching JB; Hamid O; Liepa AM; Wijayawardana S; Russo F; Walgren RA; Zimmermann AH; Hozak RR; Bell-McGuinn KM; Powles T;
    Lancet Oncol; 2020 Jan; 21(1):105-120. PubMed ID: 31753727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.
    Giannatempo P; Pond GR; Sonpavde G; Raggi D; Naik G; Galsky MD; Bellmunt J; Necchi A
    Eur Urol; 2016 Apr; 69(4):624-633. PubMed ID: 26497923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
    Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
    Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.
    Heymach JV; Lockwood SJ; Herbst RS; Johnson BE; Ryan AJ
    Ann Oncol; 2014 Oct; 25(10):1941-1948. PubMed ID: 25057173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer: a randomized phase 2 PrECOG study (PrE0501).
    Aisner J; Manola JB; Dakhil SR; Stella PJ; Sovak MA; Schiller JH
    J Thorac Oncol; 2013 Aug; 8(8):1075-83. PubMed ID: 23689430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.
    Ramlau R; Gorbunova V; Ciuleanu TE; Novello S; Ozguroglu M; Goksel T; Baldotto C; Bennouna J; Shepherd FA; Le-Guennec S; Rey A; Miller V; Thatcher N; Scagliotti G
    J Clin Oncol; 2012 Oct; 30(29):3640-7. PubMed ID: 22965962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
    Guan Z; Xu B; DeSilvio ML; Shen Z; Arpornwirat W; Tong Z; Lorvidhaya V; Jiang Z; Yang J; Makhson A; Leung WL; Russo MW; Newstat B; Wang L; Chen G; Oliva C; Gomez H
    J Clin Oncol; 2013 Jun; 31(16):1947-53. PubMed ID: 23509322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin.
    Jones R; Crabb S; Chester J; Elliott T; Huddart R; Birtle A; Evans L; Lester J; Jagdev S; Casbard A; Huang C; Madden TA; Griffiths G
    BJU Int; 2020 Aug; 126(2):292-299. PubMed ID: 32336008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
    Morabito A; Piccirillo MC; Falasconi F; De Feo G; Del Giudice A; Bryce J; Di Maio M; De Maio E; Normanno N; Perrone F
    Oncologist; 2009 Apr; 14(4):378-90. PubMed ID: 19349511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.